Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123 I-MIBG and 131 I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124 I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124 I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124 I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124 I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123 I/ 131 I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124 I-MIBG PET/CT are required.
Background
Neuroblastoma (NB) is the most common extra-cranial solid tumor in pediatric patients and originates from sympathetic cells derived from the neural crest. Bone and bone marrow metastases are quite common and, if present, result in a poor prognosis [1, 2] . Many studies have been reported the important role of 123 I-Meta-iodobenzylguanidine (MIBG) at the time of first staging and at the evaluation of treatment response, especially after induction chemotherapy [3] [4] [5] . Moreover, 123 I-MIBG scan is required when NB relapse is suspected and may establish the basis for the use of a targeted radionuclide therapy with 131 I-MIBG [6] . The principal limitation of conventional nuclear medicine in neuroblastoma (mainly 123 I-MIBG scan) is related to its relative low spatial resolution when compared with other radiological and functional techniques such as CT, MRI and PET, similarly to what happens in other pediatric tumors [7] [8] [9] [10] [11] [12] [13] .
MIBG labeled with 124 I, a positron emitting isotope suitable for PET imaging, got increased interest in clinical practice [14] [15] [16] [17] . The target of this radiocompound should be the capability of binding noradrenalin receptors as it happens with 123 I-MIBG, but with a higher image quality and sensitivity granted by PET hardware [14] . However, limited data exist about the diagnostic accuracy of 124 I-MIBG PET in NB.
We present the preliminary experience of the PET Pediatric AIMN (Italian Association of Nuclear Medicine) InterGroup with 124 I-MIBG PET/CT in two pediatric patients diagnosed with neuroblastoma in order to highlight the improvement in diagnostic accuracy provided by 124 I-MIBG PET/CT compared to the conventional imaging work-up assessing whether 124 I-MIBG PET/CT could detect as many or more neuroblastoma lesions than 123 I/ 131 I-MIBG imaging. Case report III -with involvement of the left kidney and the homolateral adrenal gland. The patient had undergone neoadjuvant chemotherapy (cisplatin, etoposide and VP 16) before radical resection of the large abdominal mass. One year after surgery, the patient was referred for 131 I-MIBG therapy (dose: 10 GBq) for a pulmonary relapse detected by a computed tomography (CT) exam. The 123 I-MIBG pre-therapy and the 131 I-post-therapy whole body scans depicted a single focal round-shaped uptake in the right lung. A week later, the child was proposed to scan with the experimental radiopharmaceutical 124 I-MIBG for compassionate use, regulated by Legislative Decree No. 219/2006. After receiving written consent from the parents, the patient was evalu-ated by PET/CT at 24h and 48h after the administration of 50 MBq of 124 I-MIBG (radiochemical purity > 95%) ( Fig. 1) . The PET/CT study ( Fig. 2 ) confirmed the finding detected by both 123 I-MIBG scintigraphy and 131 I-post-therapy whole body scan allowing a better characterization and localization of the finding in the basis of the right lung.
Case series

Case 1. Taking advantage of the better spatial resolution of 124 I-MIBG PET/CT
Afterwards, the patient underwent metastasectomy and the disease had a favorable course confirmed by a subsequent 123 I-MIBG scintigraphy and a chest CT performed three and six months later, respectively. Nevertheless, the patient developed lumbar pain and signs of paraparesis a few months later, and a whole body CT with contrast medium revealed diffuse metastases to both lungs, abdominal lymph nodes and the fifth lumbar vertebra. Therefore the patient was referred for a second course of 131 I-MIBG therapy. The 131 I-MIBG post-therapy whole body scan ( Fig. 3 ) was able to highlight all the lesions demonstrated by the CT scan, but pre-therapy 124 I-MIBG PET/CT yielded a very good definition of the extent of disease ( Fig. 4 ), demonstrating also the involvement of the medullary canal by the lesion located in the L3 vertebra, explaining the origin of the symptomatology of the patient, and revealed faint foci in L1, L4, L5 and sacrum ( Fig. 5 ). On the basis of the clinical condition and imaging findings, the patient underwent a further treatment with 131 I-MIBG, with a delivered dose of 10 GBq (270 mCi). Case report
Case 2. Depiction of all metastatic sites in one single full-body exam
Patient No. 2 was a 6-year-old boy with left adrenal gland neuroblastoma (stage IV) diagnosed when he was 1-year-old. The pathologic history had showed persistent bone disease involvement although the patient had already been treated with surgery, radiotherapy, chemotherapy and auto-transplantation over the years. After performing a follow-up 123 I-MIBG scintigraphy in another center for restaging purposes, he was referred to our department to receive a course of 9.9 GBq (270 mCi) 131 I-MIBG. The 131 I-MIBG post-therapy scan showed diffuse osseous disease (Fig. 6A, B) including the skull, the left scapula, several vertebrae, the right and left iliac bones, the ischiatic spine, the proximal part of the left tibia and the bone marrow canal of the right femur. After gaining informed consent from the patient, 124 I-MIBG PET/CT was also performed for compassionate use and was able to visualize the same lesions as detected by the planar scintigraphy with 131 I-MIBG ( Fig. 6C-F) clearly providing images with better spatial resolution in all the bone districts. 
Case report
Discussion
Although MIBG, radiolabeled with 123 I, has high sensitivity (around 90%) and specificity close to 100% in the diagnosis of neuroblastoma [17] , nevertheless an important role of labeled MIBG is also prospectively to evaluate the feasibility of 131 I-MIBG radiometabolic therapy, which can be an additional therapeutic option in case of disseminated metastatic disease in which tumor cells have retained the capability of concentrating MIBG [6] .
From this point of view, 124 I-MIBG PET/CT represents a potential method to estimate radiation dose to normal organs, as well as tumors, prior to 131 I-MIBG treatment and provide a more accurate quantification of tracer distribution because of its favorable characteristics, such as full-body tomographic capability from PET and a similar half-life (4.2 days) to 131 I (8.02 days) [15] .
Despite this important aspect, only few reports published in literature regarded the use of 124 I-MIBG in adult patients with neural crest tumors [14, 16] and, to the best of our knowledge, only one child with neuroblastoma has been studied with 124 I-MIBG PET/CT so far [18] , providing data on dosimetry. Organ-absorbed doses for the salivary glands, heart wall and liver were 98.0 Gy, 36.5 Gy, and 34.3 Gy, respectively, whereas tumor-absorbed dose range was 143.9-1,641.3 Gy [18] .
Many other studies investigated the role of PET/CT using other tracers such as 18 F-DOPA [7, 19] , 68 Ga-labelled somatostatin analogues and 18 F-FDG in patients with neuroblastoma [20] . Anyway, although these tracers can provide an excellent diagnostic accuracy in patients affected by neuroblastoma, nevertheless the labeled pharmaceutical has a metabolic behavior which is similar but not equal to iodine-labeled MIBG.
In our series, we investigated if 124 I-MIBG PET/CT could be considered a valuable tool in the diagnostic work-up of pediatric patient with advanced neuroblastoma.
From our experience, 124 I-MIBG PET/CT provides high-resolution images and may offer valuable information regarding the extension of the lesion and the involvement of different types of tissue, addressing the most appropriate clinical management between surgical treatment and medical therapy [21] . In the present study, with the limit of lack of SPECT/CT, we could compare in our patients images obtained with 123 I-MIBG scintigraphy, 131 I-MIBG scintigraphy and with 124 I-MIBG PET/CT, with the latter providing the same e information about the tumor location in the case of the single round-shaped pulmonary lesion (patient n. 1).
In 
Case report
Since metastatic spread of neuroblastoma may occur over the full length of the skeleton and since MIBG does not present uptake in the brain, 124 I-MIBG gives excellent images of the skull and so is useful to detect secondary lesions in this anatomical region, which is a relatively frequent site of metastasis. Likewise, 124 I-MIBG PET/CT should be performed in full body modality from the vertex of the skull to the feet.
A possible limitation in evaluating pediatric patients with 124 I-MIBG PET/CT is the relatively higher radiation dose delivered (0.25 mSv/MBq) when compared to 123 I-MIBG (0.019 mSv/MBq). Nevertheless, the improved characteristics of modern PET/CT scanners allow limiting the administered dose while maintaining an adequate image quality [22] . Moreover, the additional dose can be considered negligible by comparison if 124 I-MIBG is performed as a pre-therapy evaluation tool before 131 I-MIBG treatment.
Although there is lack of information in literature, this preliminary experience shows promising results for 124 I-MIBG PET/CT; anyway, a large validation and a standardization of the technique is needed, such as for the optimal timing of 124 I-MIBG PET imaging acquisition.
Multicenter investigations would be desirable, in order to foster the possible role of this technique in evaluating patients with neuroblastoma. At present, we could at least suggest to perform a 124 I-MIBG PET/CT as a pre-therapy examination, given the high diagnostic accuracy demonstrated by our cases, and for restaging, especially when doubtful findings are evidenced by scintigraphic imaging with 123 I or 131 I-MIBG.
